메뉴 건너뛰기




Volumn 6, Issue 15, 2015, Pages 13790-13802

A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers

Author keywords

Angiogenesis; FGF8; Hormone regulated cancer; Pentraxin; Peptide

Indexed keywords

ANDROGEN; ARPCA PEPTIDE; ARPVA PEPTIDE; BOLDENONE; CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR 8B; FIBROBLAST GROWTH FACTOR RECEPTOR 1; KI 67 ANTIGEN; PENTAPEPTIDE; PENTRAXIN 3; PROTEOHEPARAN SULFATE; STEROID HORMONE; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; PEPTIDE FRAGMENT; SERUM AMYLOID P;

EID: 84931088261     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3831     Document Type: Article
Times cited : (26)

References (45)
  • 2
    • 0026738943 scopus 로고
    • Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells
    • Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H and Matsumoto K. Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci U S A. 1992; 89:8928-8932.
    • (1992) Proc Natl Acad Sci U S A. , vol.89 , pp. 8928-8932
    • Tanaka, A.1    Miyamoto, K.2    Minamino, N.3    Takeda, M.4    Sato, B.5    Matsuo, H.6    Matsumoto, K.7
  • 4
    • 34249990979 scopus 로고    scopus 로고
    • Role of fibroblast growth factor 8 in growth and progression of hormonal cancer
    • Mattila MM and Harkonen PL. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev. 2007; 18:257-266.
    • (2007) Cytokine Growth Factor Rev. , vol.18 , pp. 257-266
    • Mattila, M.M.1    Harkonen, P.L.2
  • 5
    • 0034547972 scopus 로고    scopus 로고
    • The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells
    • Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ and Roy-Burman P. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res. 2000; 60:6730-6736.
    • (2000) Cancer Res. , vol.60 , pp. 6730-6736
    • Song, Z.1    Powell, W.C.2    Kasahara, N.3    van Bokhoven, A.4    Miller, G.J.5    Roy-Burman, P.6
  • 6
    • 34748912386 scopus 로고    scopus 로고
    • Androgen-response elements in hormone-refractory prostate cancer:implications for treatment development
    • Hsieh AC, Small EJ and Ryan CJ. Androgen-response elements in hormone-refractory prostate cancer:implications for treatment development. The Lancet Oncology. 2007; 8:933-939.
    • (2007) The Lancet Oncology. , vol.8 , pp. 933-939
    • Hsieh, A.C.1    Small, E.J.2    Ryan, C.J.3
  • 8
    • 70249146546 scopus 로고    scopus 로고
    • Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands
    • Schwertfeger KL. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets. 2009; 10:632-644.
    • (2009) Curr Drug Targets. , vol.10 , pp. 632-644
    • Schwertfeger, K.L.1
  • 10
    • 0036733760 scopus 로고    scopus 로고
    • Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia
    • Song Z, Wu X, Powell WC, Cardiff RD, Cohen MB, Tin RT, Matusik RJ, Miller GJ and Roy-Burman P. Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res. 2002; 62:5096-5105.
    • (2002) Cancer Res. , vol.62 , pp. 5096-5105
    • Song, Z.1    Wu, X.2    Powell, W.C.3    Cardiff, R.D.4    Cohen, M.B.5    Tin, R.T.6    Matusik, R.J.7    Miller, G.J.8    Roy-Burman, P.9
  • 11
    • 0032546230 scopus 로고    scopus 로고
    • Downregulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems
    • Rudra-Ganguly N, Zheng J, Hoang AT and Roy-Burman P. Downregulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems. Oncogene. 1998; 16:1487-1492.
    • (1998) Oncogene. , vol.16 , pp. 1487-1492
    • Rudra-Ganguly, N.1    Zheng, J.2    Hoang, A.T.3    Roy-Burman, P.4
  • 12
    • 17644423119 scopus 로고    scopus 로고
    • Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility
    • Garlanda C, Bottazzi B, Bastone A and Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005; 23:337-366.
    • (2005) Annu Rev Immunol. , vol.23 , pp. 337-366
    • Garlanda, C.1    Bottazzi, B.2    Bastone, A.3    Mantovani, A.4
  • 17
    • 34548189432 scopus 로고    scopus 로고
    • Role of the soluble pattern recognition receptor PTX3 in vascular biology
    • Presta M, Camozzi M, Salvatori G and Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med. 2007; 11:723-738.
    • (2007) J Cell Mol Med. , vol.11 , pp. 723-738
    • Presta, M.1    Camozzi, M.2    Salvatori, G.3    Rusnati, M.4
  • 21
    • 0035901963 scopus 로고    scopus 로고
    • FGF-8b increases angiogenic capacity and tumor growth of androgenregulated S115 breast cancer cells
    • Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppanen JA and Harkonen PL. FGF-8b increases angiogenic capacity and tumor growth of androgenregulated S115 breast cancer cells. Oncogene. 2001; 20:2791-2804.
    • (2001) Oncogene. , vol.20 , pp. 2791-2804
    • Mattila, M.M.1    Ruohola, J.K.2    Valve, E.M.3    Tasanen, M.J.4    Seppanen, J.A.5    Harkonen, P.L.6
  • 24
    • 34250640742 scopus 로고    scopus 로고
    • The gelatin sponge-chorioallantoic membrane assay
    • Ribatti D, Nico B, Vacca A and Presta M. The gelatin sponge-chorioallantoic membrane assay. Nat Protoc. 2006; 1:85-91.
    • (2006) Nat Protoc. , vol.1 , pp. 85-91
    • Ribatti, D.1    Nico, B.2    Vacca, A.3    Presta, M.4
  • 26
    • 0033614366 scopus 로고    scopus 로고
    • FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease
    • Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE and Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene. 1999; 18:2755-2761.
    • (1999) Oncogene. , vol.18 , pp. 2755-2761
    • Dorkin, T.J.1    Robinson, M.C.2    Marsh, C.3    Bjartell, A.4    Neal, D.E.5    Leung, H.Y.6
  • 27
    • 42949151299 scopus 로고    scopus 로고
    • A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows antitumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions
    • Maruyama-Takahashi K, Shimada N, Imada T, Maekawa-Tokuda Y, Ishii T, Ouchi J, Kusaka H, Miyaji H, Akinaga S, Tanaka A and Shitara K. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows antitumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions. Prostate. 2008; 68:640-650.
    • (2008) Prostate. , vol.68 , pp. 640-650
    • Maruyama-Takahashi, K.1    Shimada, N.2    Imada, T.3    Maekawa-Tokuda, Y.4    Ishii, T.5    Ouchi, J.6    Kusaka, H.7    Miyaji, H.8    Akinaga, S.9    Tanaka, A.10    Shitara, K.11
  • 30
    • 22244492038 scopus 로고    scopus 로고
    • Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor
    • Brown AP, Courtney CL, King LM, Groom SC and Graziano MJ. Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor. Toxicol Pathol. 2005; 33:449-455.
    • (2005) Toxicol Pathol. , vol.33 , pp. 449-455
    • Brown, A.P.1    Courtney, C.L.2    King, L.M.3    Groom, S.C.4    Graziano, M.J.5
  • 31
    • 72249111162 scopus 로고    scopus 로고
    • Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: longpentraxin 3 as a novel antiangiogenic FGF2-antagonist
    • Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A and Presta M. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: longpentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur Cytokine Netw. 2009; 20:225-234.
    • (2009) Eur Cytokine Netw. , vol.20 , pp. 225-234
    • Alessi, P.1    Leali, D.2    Camozzi, M.3    Cantelmo, A.4    Albini, A.5    Presta, M.6
  • 32
    • 26644471951 scopus 로고    scopus 로고
    • Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
    • Casanovas O, Hicklin DJ, Bergers G and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8:299-309.
    • (2005) Cancer Cell. , vol.8 , pp. 299-309
    • Casanovas, O.1    Hicklin, D.J.2    Bergers, G.3    Hanahan, D.4
  • 33
    • 67449132021 scopus 로고    scopus 로고
    • How well do angiogenesis inhibitors work? Biomarkers of response prove elusive
    • Brower V. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. J Natl Cancer Inst. 2009; 101:846-847.
    • (2009) J Natl Cancer Inst. , vol.101 , pp. 846-847
    • Brower, V.1
  • 34
    • 0034640103 scopus 로고    scopus 로고
    • Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity
    • Plotnikov AN, Hubbard SR, Schlessinger J and Mohammadi M. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell. 2000; 101:413-424.
    • (2000) Cell. , vol.101 , pp. 413-424
    • Plotnikov, A.N.1    Hubbard, S.R.2    Schlessinger, J.3    Mohammadi, M.4
  • 36
    • 79959713140 scopus 로고    scopus 로고
    • Fibroblast growth factors and their receptors in cancer
    • Wesche J, Haglund K and Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437:199-213.
    • (2011) Biochem J. , vol.437 , pp. 199-213
    • Wesche, J.1    Haglund, K.2    Haugsten, E.M.3
  • 37
    • 69249216604 scopus 로고    scopus 로고
    • The role of fibroblast growth factors in tumor growth
    • Korc M and Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Drug Targets. 2009; 9:639-651.
    • (2009) Curr Drug Targets. , vol.9 , pp. 639-651
    • Korc, M.1    Friesel, R.E.2
  • 38
    • 80053493427 scopus 로고    scopus 로고
    • Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis
    • Lieu C, Heymach J, Overman M, Tran H and Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011; 17:6130-6139.
    • (2011) Clin Cancer Res. , vol.17 , pp. 6130-6139
    • Lieu, C.1    Heymach, J.2    Overman, M.3    Tran, H.4    Kopetz, S.5
  • 39
    • 84859415553 scopus 로고    scopus 로고
    • Molecular pathways:fibroblast growth factor signaling: a new therapeutic opportunity in cancer
    • Brooks AN, Kilgour E and Smith PD. Molecular pathways:fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012; 18:1855-1862.
    • (2012) Clin Cancer Res. , vol.18 , pp. 1855-1862
    • Brooks, A.N.1    Kilgour, E.2    Smith, P.D.3
  • 40
    • 61649100307 scopus 로고    scopus 로고
    • The FGF family: biology, pathophysiology and therapy
    • Beenken A and Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8:235-253.
    • (2009) Nat Rev Drug Discov. , vol.8 , pp. 235-253
    • Beenken, A.1    Mohammadi, M.2
  • 42
    • 75149170979 scopus 로고    scopus 로고
    • Fibroblast growth factor signalling:from development to cancer
    • Turner N and Grose R. Fibroblast growth factor signalling:from development to cancer. Nat Rev Cancer. 2010; 10:116-129.
    • (2010) Nat Rev Cancer. , vol.10 , pp. 116-129
    • Turner, N.1    Grose, R.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.